EUVIMEDEUVIMED entdecken
Fallbericht

Pembrolizumab-Induced Bullous Pemphigoid: Navigating Diagnostic Challenges and Treatment Resistance

Camille Moeckel, Sara Ferguson

Cutis · 01.05.2026 · 5 (117)

DOI: 10.12788/cutis.1411 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cutis, erschienen am 01.05.2026. Verfasst von Camille Moeckel und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Penn State College of Medicine, Hershey, Pennsylvania. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Pemphigoid, Bullous, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedPemphigoid, BullousAntineoplastic Agents, ImmunologicalHumansMaleAged, 80 and overUrinary Bladder Neoplasms

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Dermatology, Penn State College of Medicine, Hershey, Pennsylvania.

Zitieren

APA

Moeckel, C., & Ferguson, S. (2026). Pembrolizumab-Induced Bullous Pemphigoid: Navigating Diagnostic Challenges and Treatment Resistance. Cutis, 5(117). https://doi.org/10.12788/cutis.1411

Vancouver

Moeckel C, Ferguson S. Pembrolizumab-Induced Bullous Pemphigoid: Navigating Diagnostic Challenges and Treatment Resistance. Cutis. 2026;5(117). doi:10.12788/cutis.1411

BibTeX
@article{Moeckel2026,
  author = {Moeckel, Camille and Ferguson, Sara},
  title = {Pembrolizumab-Induced Bullous Pemphigoid: Navigating Diagnostic Challenges and Treatment Resistance},
  journal = {Cutis},
  year = {2026},
  volume = {5},
  number = {117},
  doi = {10.12788/cutis.1411}
}
Kostenlos starten →